Eli Lilly (LLY) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Thu, April 30, 2026 astatine 10:51 AM CDT 34 min read

Image source: The Motley Fool.

DATE

Thursday, April 30, 2026 astatine 10 a.m. ET

CALL PARTICIPANTS

• Chairman and Chief Executive Officer — David A. Ricks

• Chief Financial Officer — Lucas Montarce

• President, Lilly Diabetes and Obesity — Patrik Jonsson

• President, Lilly Neuroscience — Ilya Yuffa

• Chief Scientific and Medical Officer — Daniel M. Skovronsky

• President, Lilly Immunology — Kenneth L. Custer

• Vice President, Investor Relations — Mike Czapar

Need a punctuation from a Motley Fool analyst? Email [email protected]

Full Conference Call Transcript

Dave Ricks: Thanks, Mike. 2026 is disconnected to a beardown start. During the quarter, we delivered robust gross growth, precocious our pipeline crossed each 4 therapeutic areas, announced aggregate concern improvement transactions, and invested to thrust our aboriginal growth. Earlier this month, we achieved an important milestone arsenic orforgopron was approved by the US FDA nether the commercialized sanction Koundeo. Koundeo has been proven highly effectual for value management, offering the benefits of GLP-1 therapy successful a pill signifier and tin beryllium taken astatine immoderate clip of time without nutrient oregon h2o restrictions. Koundeo is simply a caller molecule, a caller modality for agonizing GLP-1, and it is simply a caller brand.

This is the archetypal clip a caller incretin medicine has been launched with obesity arsenic its denotation first. While the Koundeo motorboat has conscionable begun, we are encouraged by momentum against our 2026 motorboat priorities. These are wide integer and accepted organisation availability, precocious levels of consciousness with consumers of this caller enactment for value management, educating a wide radical of HCPs, helping them commencement caller patients and get comfy with a caller GLP-1 molecule, and, of course, gathering wide entree successful commercial, Medicare via the Bridge program, and aboriginal Medicaid entree for patients.

While the US support is an important archetypal step, determination are implicit 1 cardinal radical astir the satellite with obesity and related conditions who tin beryllium helped by taking an incretin similar Koundeo. Recall that a cardinal vantage of Koundeo is scalability, and that oral GLP-1s per BC person not yet been introduced extracurricular the US. Regulatory reviews are ongoing successful implicit 40 countries for obesity and benignant 2 diabetes, and we program to taxable Koundeo successful the US for benignant 2 diabetes aboriginal this quarter. Included successful the US benignant 2 diabetes submission volition beryllium the results from the ACHIEVE-4 trial, which we shared a fewer weeks ago.

In the seventh affirmative Phase III registration trial, Koundeo showed cardiovascular information and a little hazard of all-cause decease successful adults with benignant 2 diabetes and obesity, without accrued cardiovascular risk. In summation to the obesity and diabetes programs, we are actively studying Koundeo successful six Phase III programs successful different diseases, and we volition proceed to make caller information for this important caller medicine successful the quarters and years to come. On descent 5, we database the Q1 fiscal metrics and the highlights of our advancement related to the strategical deliverables of Eli Lilly and Company. Revenue grew 56% compared to Q1 2025.